alnylam
The Global Study Lead (Sr. Manager, Clinical Operations) is responsible for leading the operational planning and execution of global clinical trials from start‑up through closeout, ensuring timelines, budgets, and quality standards are met. This hybrid role, based in Maidenhead, provides leadership to cross‑functional teams, oversees CRO and vendor management, and drives risk mitigation and compliance with regulatory requirements.
Headquarters
Cambridge, Massachusetts, United States
Company Size
1001-5000 employees
Founded
2002
Alnylam is a biopharmaceutical company that has pioneered RNA interference (RNAi) therapeutics, an innovative class of medicines that treats diseases by silencing the genes that cause or contribute to them. The company develops RNAi-based medicines targeting both rare and prevalent diseases across multiple therapeutic areas, with approved products and a robust investigational pipeline. Driven by science and inspired by patients, Alnylam is committed to delivering transformational medicines that address diseases at their genetic source.
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for alnylam.
alnylam didn’t post a salary, so this is our estimate from similar listings.
28% below the average for this role